- Issuer
- Global X
- Inception Date
- Nov 8, 2018
- Region
- Global (Broad)
- Category
- Health & Biotech Equities
- Leveraged
- 1x (No leverage)
- Index Tracked
- S&P Biotechnology Select Industry Index
- Domicile
- Australia
- Distribution Policy
- Distributing
- Asset Class
- Equity
- Asset Class Style
- Growth
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
CURE.AX Performance Chart
Global X S&P Biotech ETF (CURE.AX) is up 22.7% since the beginning of the year. CURE.AX is currently trading at A$76 per share. Investors who bought A$1,000 worth of CURE.AX shares 5 years ago would now be looking at an investment worth A$1,314.
Loading charts...
Returns By Period
Global X S&P Biotech ETF (CURE.AX) has returned 22.66% so far this year and 65.69% over the past 12 months.
Global X S&P Biotech ETF
- 1D
- 0.58%
- 1M
- 17.05%
- 6M
- 20.39%
- YTD
- 22.66%
- 1Y
- 65.69%
- 3Y*
- 21.60%
- 5Y*
- 5.62%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 0.12%
- 1M
- 1.38%
- 6M
- 4.49%
- YTD
- 5.58%
- 1Y
- 12.98%
- 3Y*
- 18.01%
- 5Y*
- 13.12%
- 10Y*
- 14.27%
CURE.AX Monthly Returns History
Based on dividend-adjusted daily data since Nov 8, 2018, CURE.AX's average daily return is +0.05%, while the average monthly return is +0.95%. At this rate, an investment would double in approximately 6.1 years.
Historically, 49% of months were positive and 51% were negative. The best month was Jun 2026 with a return of +22.5%, while the worst month was Jan 2022 at -18.7%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 9 months.
On a daily basis, CURE.AX closed higher 48% of trading days. The best single day was Jan 8, 2019 with a return of +11.8%, while the worst single day was Mar 13, 2020 at -8.5%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -0.55% | -2.03% | -1.85% | 2.28% | 5.85% | 22.53% | -3.31% | 22.66% | |||||
| 2025 | 3.19% | -6.93% | -4.50% | -5.26% | -1.35% | 2.17% | 4.38% | 4.04% | 9.18% | 12.65% | 10.71% | -3.28% | 25.25% |
| 2024 | 2.66% | 14.04% | -7.16% | -10.17% | 1.99% | 5.11% | 9.04% | -3.14% | -4.25% | 5.65% | 2.38% | -5.57% | 8.13% |
| 2023 | 2.25% | -1.30% | -8.50% | 6.54% | 7.00% | -1.38% | -0.68% | -1.29% | -7.24% | -10.65% | 9.83% | 19.41% | 10.63% |
| 2022 | -18.71% | -3.34% | -1.73% | -11.37% | -7.09% | 7.91% | 9.63% | 3.09% | -0.14% | 7.33% | -7.84% | 0.56% | -22.98% |
| 2021 | 3.80% | -4.51% | -8.23% | 2.88% | -5.90% | 8.61% | -6.74% | 7.14% | -3.31% | -4.09% | -3.69% | -2.87% | -17.10% |
Benchmark Metrics
Global X S&P Biotech ETF has an annualized alpha of 11.17%, beta of 0.04, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since November 08, 2018.
- This ETF participated in 115.69% of S&P 500 Index downside but only 80.77% of its upside - more exposed to losses than it benefited from rallies.
- Beta of 0.04 may look defensive, but with R2 of 0.00 this ETF is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this ETF's risk.
- R2 of 0.00 means this ETF moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 11.17%
- Beta
- 0.04
- R²
- 0.00
- Upside Capture
- 80.77%
- Downside Capture
- 115.69%
Expense Ratio
CURE.AX has an expense ratio of 0.45%, placing it in the medium range.
Return for Risk
Risk / Return Rank
CURE.AX ranks 91 for risk / return — in the top 91% of ETFs on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Global X S&P Biotech ETF (CURE.AX) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| CURE.AX | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.34 | ||
| Sortino ratioReturn per unit of downside risk | +1.66 | ||
| Omega ratioGain probability vs. loss probability | 1.43 | 1.24 | +0.19 |
| Calmar ratioReturn relative to maximum drawdown | 5.80 | 1.11 | +4.68 |
| Martin ratioReturn relative to average drawdown | 14.61 | 3.10 | +11.51 |
Dividends
Dividend History
Global X S&P Biotech ETF provided a 0.00% dividend yield over the last twelve months, with an annual payout of A$0.00 per share.
| Period | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend | A$0.00 | A$0.00 | A$0.00 | A$0.00 | A$0.02 | A$6.26 | A$6.76 | A$1.17 |
Dividend yield | 0.00% | 0.00% | 0.00% | 0.00% | 0.06% | 11.64% | 9.47% | 2.05% |
Monthly Dividends
The table displays the monthly dividend distributions for Global X S&P Biotech ETF. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | A$0.00 | A$0.00 | A$0.00 | A$0.00 | A$0.00 | A$0.00 | A$0.00 | A$0.00 | |||||
| 2025 | A$0.00 | A$0.00 | A$0.00 | A$0.00 | A$0.00 | A$0.00 | A$0.00 | A$0.00 | A$0.00 | A$0.00 | A$0.00 | A$0.00 | A$0.00 |
| 2024 | A$0.00 | A$0.00 | A$0.00 | A$0.00 | A$0.00 | A$0.00 | A$0.00 | A$0.00 | A$0.00 | A$0.00 | A$0.00 | A$0.00 | A$0.00 |
| 2023 | A$0.00 | A$0.00 | A$0.00 | A$0.00 | A$0.00 | A$0.00 | A$0.00 | A$0.00 | A$0.00 | A$0.00 | A$0.00 | A$0.00 | A$0.00 |
| 2022 | A$0.00 | A$0.00 | A$0.00 | A$0.00 | A$0.00 | A$0.02 | A$0.00 | A$0.00 | A$0.00 | A$0.00 | A$0.00 | A$0.00 | A$0.02 |
| 2021 | A$0.00 | A$0.00 | A$0.00 | A$0.00 | A$0.00 | A$6.26 | A$0.00 | A$0.00 | A$0.00 | A$0.00 | A$0.00 | A$0.00 | A$6.26 |
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Global X S&P Biotech ETF. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Global X S&P Biotech ETF was 59.81%, occurring on May 12, 2022. Recovery took 1052 trading sessions.
The current Global X S&P Biotech ETF drawdown is 5.45%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-59.81%May 2022 | 1y 3mo | 4y 1mo | 5y 4moFeb 2021 - Jun 2026 | Bear market2022 |
-27.57%Mar 2020 | 21d | 1mo 9d | 2moFeb 2020 - Apr 2020 | COVID crash2020 |
-17.75%Sep 2020 | 1mo 17d | 1mo 29d | 3mo 16dJul 2020 - Nov 2020 | — |
-16.63%Oct 2019 | 6mo 4d | 1mo 17d | 7mo 21dApr 2019 - Nov 2019 | — |
-13.56%Dec 2018 | 1mo 18d | 22d | 2mo 10dNov 2018 - Jan 2019 | Rate-hike selloffLate 2018 |
Drawdown Indicators
| CURE.AX | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -59.81% | -41.07% | -18.74% |
Max Drawdown (1Y)Largest decline over 1 year | -11.68% | -11.69% | +0.01% |
Max Drawdown (3Y)Largest decline over 3 years | -28.37% | -17.74% | -10.63% |
Max Drawdown (5Y)Largest decline over 5 years | -50.92% | -22.01% | -28.91% |
Max Drawdown (10Y)Largest decline over 10 years | — | -24.71% | — |
Current DrawdownCurrent decline from peak | -5.45% | -0.60% | -4.85% |
Average DrawdownAverage peak-to-trough decline | -27.38% | -11.02% | -16.36% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 4.66% | 4.20% | +0.46% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Build a portfolio with CURE.AX
Add Global X S&P Biotech ETF to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with CURE.AX